Table 2.
Clinical inputs
| Parameter | Vericiguat + GDMT | GDMT alone |
|---|---|---|
| Rate (events per 100 patient-years) of primary composite outcome of first HF hospitalization and CV mortality | 33.6a | 37.8a |
| Estimated cumulative proportion of patients experiencing composite outcome at end of year | ||
| Year 1 | 28.5% | 31.5% |
| Year 2 | 48.9% | 53.0% |
| Year 3 | 63.5% | 67.8% |
| Breakdown of primary composite outcome | ||
| Proportion of first HF hospitalization | 77.0%a | 76.9%a |
| Proportion of CV mortality | 23.0%a | 23.1%a |
| Estimated cumulative proportion of patients experiencing first HF hospitalization at end of year | ||
| Year 1 | 22.0% | 24.2% |
| Year 2 | 37.7% | 40.8% |
| Year 3 | 48.9% | 52.1% |
| Estimated cumulative proportion of patients experiencing CV mortality at end of year | ||
| Year 1 | 6.6% | 7.3% |
| Year 2 | 11.1% | 12.3% |
| Year 3 | 14.6% | 15.7% |
| Proportion of patients ever experiencing first HF hospitalization who further experienced subsequent HF hospitalization | 77.0%a | 78.8%a |
| Estimated cumulative proportion of patients experiencing subsequent HF hospitalization at end of year | ||
| Year 1 | 16.9% | 19.1% |
| Year 2 | 29.0% | 32.1% |
| Year 3 | 37.7% | 41.1% |
CV cardiovascular, GDMT guideline-directed medical therapy, HF heart failure
aArmstrong et al. [8]